Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 710 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma May 20, 2026 Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... March 7, 2024 Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... December 5, 2024 Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Load more HOT NEWS What to Know About Biomarker Testing for Lung Cancer: An Expert... Thank you! Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in...
